{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-25-000044","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.452887+00:00","generated_at":"2026-05-17T01:30:32.054492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised","bullets":["GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.","Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.","Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.","Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.","Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-25-000044","json":"https://secwatch.observer/filing/0000882095-25-000044.json","markdown":"https://secwatch.observer/filing/0000882095-25-000044.md","text":"https://secwatch.observer/filing/0000882095-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/0000882095-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/gild-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:30:32.054492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}